Silo Pharma Expands License Agreement and Patent Portfolio
23. Juni 2022 08:05 ET
|
Silo Pharma, Inc.
Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders ENGLEWOOD CLIFFS, N.J., June ...
Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology
07. April 2021 08:01 ET
|
Silo Pharma, Inc.
Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company...